<?xml version="1.0" encoding="UTF-8"?>
<p id="Par30">This trial aims to:
 <list list-type="order">
  <list-item>
   <p id="Par31">quantify the causal impact of early access to ART for all HIV-infected adults, irrespective of CD4 count or clinical staging, on ART retention and viral suppression in a public sector health system;</p>
  </list-item>
  <list-item>
   <p id="Par32">quantify the causal impacts of EAAA on average health care expenditures and resources use;</p>
  </list-item>
  <list-item>
   <p id="Par33">quantify the causal impacts of EAAA on patient satisfaction, patientsâ€™ welfare, and provider satisfaction;</p>
  </list-item>
  <list-item>
   <p id="Par34">to establish the feasibility and acceptability of EAAA;</p>
  </list-item>
  <list-item>
   <p id="Par35">establish the role of PLHIV, traditional leaders, civil society, and communities for implementing EAAA;</p>
  </list-item>
  <list-item>
   <p id="Par36">determine the social and institutional processes throughout EAAA implementation to help interpret differences in health service delivery and patient experiences of ART initiation, adherence, and retention before and after the intervention;</p>
  </list-item>
  <list-item>
   <p id="Par37">estimate the potential change in HIV incidence and ART program size if EAAA were to be implemented nationwide in Swaziland; and</p>
  </list-item>
  <list-item>
   <p id="Par38">predict the long-term cost-effectiveness of EAAA.</p>
  </list-item>
 </list>
</p>
